{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:08Z","timestamp":1786979888667,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001287","name":"Elsa U. Pardee Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100001287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-12-044-01"],"award-info":[{"award-number":["RSG-12-044-01"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CBET1510015"],"award-info":[{"award-number":["CBET1510015"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00259-021-05406-z","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T02:02:40Z","timestamp":1623463360000},"page":"4246-4258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Transport-driven engineering of liposomes for delivery of \u03b1-particle radiotherapy to solid tumors: effect on inhibition of tumor progression and onset delay of spontaneous metastases"],"prefix":"10.1007","volume":"48","author":[{"given":"Aprameya","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omkar","family":"Bhatavdekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaina","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sempkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Josefsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Pacheco-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaver M.","family":"Bhujwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sgouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-326X","authenticated-orcid":false,"given":"Stavroula","family":"Sofou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,12]]},"reference":[{"key":"5406_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134. https:\/\/doi.org\/10.2967\/jnumed.116.178673.","journal-title":"J Nucl Med"},{"key":"5406_CR2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2967\/jnumed.117.204651","volume":"59","author":"S Poty","year":"2018","unstructured":"Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. \u03b1-emitters for radiotherapy: from basic radiochemistry to clinical studies\u2014part 2. J Nucl Med. 2018;59:1020\u20137. https:\/\/doi.org\/10.2967\/jnumed.117.204651.","journal-title":"J Nucl Med"},{"key":"5406_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2967\/jnumed.119.229229","volume":"61","author":"M Sathekge","year":"2020","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61:62\u20139. https:\/\/doi.org\/10.2967\/jnumed.119.229229.","journal-title":"J Nucl Med"},{"key":"5406_CR4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1158\/1535-7163.mct-13-0108","volume":"12","author":"H Song","year":"2013","unstructured":"Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, et al. Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther. 2013;12:2043\u201354. https:\/\/doi.org\/10.1158\/1535-7163.mct-13-0108.","journal-title":"Mol Cancer Ther"},{"key":"5406_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev-bioeng-062117-120931","volume":"20","author":"MR McDevitt","year":"2018","unstructured":"McDevitt MR, Sgouros G, Sofou S. Targeted and nontargeted \u03b1-particle therapies. Annu Rev Biomed Eng. 2018;20:73\u201393. https:\/\/doi.org\/10.1146\/annurev-bioeng-062117-120931.","journal-title":"Annu Rev Biomed Eng"},{"key":"5406_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2478\/v10019-010-0054-4","volume":"45","author":"T Ovcaricek","year":"2011","unstructured":"Ovcaricek T, Frkovic S, Matos E, Mozina B, Borstnar S. Triple negative breast cancer\u2014prognostic factors and survival. Radiol Oncol. 2011;45:46\u201352.","journal-title":"Radiol Oncol"},{"key":"5406_CR7","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.Ccr-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-3045.","journal-title":"Clin Cancer Res"},{"key":"5406_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11864-019-0682-x","volume":"20","author":"TG Lyons","year":"2019","unstructured":"Lyons TG. Targeted therapies for triple-negative breast cancer. Curr Treat Options in Oncol. 2019;20:82. https:\/\/doi.org\/10.1007\/s11864-019-0682-x.","journal-title":"Curr Treat Options in Oncol"},{"key":"5406_CR9","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1200\/jco.2016.68.4068","volume":"34","author":"EL Mayer","year":"2016","unstructured":"Mayer EL, Burstein HJ. Chemotherapy for triple-negative breast cancer: is more better? J Clin Oncol. 2016;34:3369\u201371. https:\/\/doi.org\/10.1200\/jco.2016.68.4068.","journal-title":"J Clin Oncol"},{"key":"5406_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1021\/acs.molpharmaceut.9b00812","volume":"17","author":"S Stras","year":"2020","unstructured":"Stras S, Howe A, Prasad A, Salerno D, Bhatavdekar O, Sofou S. Growth of metastatic triple-negative breast cancer is inhibited by deep tumor-penetrating and slow tumor-clearing chemotherapy: the case of tumor-adhering liposomes with interstitial drug release. Mol Pharm. 2020;17:118\u201331. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00812.","journal-title":"Mol Pharm"},{"key":"5406_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.biomaterials.2017.03.035","volume":"130","author":"C Zhu","year":"2017","unstructured":"Zhu C, Sempkowski M, Holleran T, Linz T, Bertalan T, Josefsson A, et al. Alpha-particle radiotherapy: for large solid tumors diffusion trumps targeting. Biomaterials. 2017;130:67\u201375. https:\/\/doi.org\/10.1016\/j.biomaterials.2017.03.035.","journal-title":"Biomaterials"},{"key":"5406_CR12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1021\/mp100038h","volume":"7","author":"H Lee","year":"2010","unstructured":"Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm. 2010;7:1195\u2013208.","journal-title":"Mol Pharm"},{"key":"5406_CR13","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1073\/pnas.030420797","volume":"97","author":"H Zhou","year":"2000","unstructured":"Zhou H, Randers-Pehrson G, Waldren CA, Vannais D, Hall EJ, Hei TK. Induction of a bystander mutagenic effect of alpha particles in mammalian cells. Proc Natl Acad Sci. 2000;97:2099\u2013104. https:\/\/doi.org\/10.1073\/pnas.030420797.","journal-title":"Proc Natl Acad Sci"},{"key":"5406_CR14","first-page":"6449","volume":"49","author":"P Vaupel","year":"1989","unstructured":"Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449\u201365.","journal-title":"Cancer Res"},{"key":"5406_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/cncr.23226","volume":"112","author":"S Basu","year":"2008","unstructured":"Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive\/progesterone receptor-positive\/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose\/positron emission tomography imaging parameters. Cancer. 2008;112:995\u20131000. https:\/\/doi.org\/10.1002\/cncr.23226.","journal-title":"Cancer."},{"key":"5406_CR16","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/0008-5472.can-12-2796","volume":"73","author":"V Estrella","year":"2013","unstructured":"Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73:1524\u201335. https:\/\/doi.org\/10.1158\/0008-5472.can-12-2796.","journal-title":"Cancer Res"},{"key":"5406_CR17","first-page":"987","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987.","journal-title":"Cancer Res"},{"key":"5406_CR18","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1158\/1078-0432.ccr-16-3193","volume":"23","author":"H Lee","year":"2017","unstructured":"Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, et al. 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin Cancer Res. 2017;23:4190\u2013202. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-3193.","journal-title":"Clin Cancer Res"},{"key":"5406_CR19","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1021\/la204765r","volume":"28","author":"A Bandekar","year":"2012","unstructured":"Bandekar A, Sofou S. Floret-shaped solid domains on giant fluid lipid vesicles induced by pH. Langmuir. 2012;28:4113\u201322.","journal-title":"Langmuir."},{"key":"5406_CR20","first-page":"253","volume":"45","author":"S Sofou","year":"2004","unstructured":"Sofou S, Thomas JL, Lin H-Y, McDevitt MR, Scheinberg DA, Sgouros G. Engineered liposomes for potential a-particle therapy of metastatic cancer. J Nucl Med. 2004;45:253\u201360.","journal-title":"J Nucl Med"},{"key":"5406_CR21","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1021\/la800331a","volume":"24","author":"S Karve","year":"2008","unstructured":"Karve S, Bajagur Kempegowda G, Sofou S. Heterogeneous domains and membrane permeability in phosphatidylcholine- phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch. Langmuir. 2008;24:5679\u201388.","journal-title":"Langmuir"},{"key":"5406_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2174\/1874471011205030221","volume":"5","author":"M Alfred","year":"2012","unstructured":"Alfred M, Frank B, Christos A. Bismuth-213 and Actinium-225 \u2013 generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes. Curr Radiopharm. 2012;5:221\u20137. https:\/\/doi.org\/10.2174\/1874471011205030221.","journal-title":"Curr Radiopharm"},{"key":"5406_CR23","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.2967\/jnumed.110.077578","volume":"51","author":"T Back","year":"2010","unstructured":"Back T, Jacobsson L. The alpha-camera: a quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of alpha-particles. J Nucl Med. 2010;51:1616\u201323.","journal-title":"J Nucl Med"},{"key":"5406_CR24","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.nano.2015.03.014","volume":"11","author":"J Pacheco-Torres","year":"2015","unstructured":"Pacheco-Torres J, Mukherjee N, Walko M, L\u00f3pez-Larrubia P, Ballesteros P, Cerdan S, et al. Image guided drug release from pH-sensitive ion channel-functionalized stealth liposomes into an in vivo glioblastoma model. Nanomedicine. 2015;11:1345\u201354.","journal-title":"Nanomedicine"},{"key":"5406_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311\u201328. https:\/\/doi.org\/10.2967\/jnumed.108.058651.","journal-title":"J Nucl Med"},{"key":"5406_CR26","doi-asserted-by":"publisher","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","volume":"69","author":"H Song","year":"2009","unstructured":"Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 2009;69:8941\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1828.","journal-title":"Cancer Res"},{"key":"5406_CR27","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.1064126","volume":"294","author":"MR McDevitt","year":"2001","unstructured":"McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537\u201340.","journal-title":"Science"},{"key":"5406_CR28","unstructured":"Saltzman MW. Engineering principles for drug therapy: Oxford University Press; 2001."},{"key":"5406_CR29","doi-asserted-by":"publisher","first-page":"11671","DOI":"10.1038\/s41598-019-48298-8","volume":"9","author":"RMD Kruijff","year":"2019","unstructured":"Kruijff RMD, Raav\u00e9 R, Kip A, Molkenboer-Kuenen J, Morgenstern A, Bruchertseifer F, et al. The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier. Sci Rep. 2019;9:11671. https:\/\/doi.org\/10.1038\/s41598-019-48298-8.","journal-title":"Sci Rep"},{"key":"5406_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1088\/0031-9155\/56\/3\/012","volume":"56","author":"J Schwartz","year":"2011","unstructured":"Schwartz J, Jaggi JS, O\u2019Donoghue JA, Ruan S, McDevitt M, Larson SM, et al. Renal uptake of Bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011;56:721\u201333. https:\/\/doi.org\/10.1088\/0031-9155\/56\/3\/012.","journal-title":"Phys Med Biol"},{"key":"5406_CR31","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1021\/jm990141f","volume":"42","author":"KA Deal","year":"1999","unstructured":"Deal KA, Davis IA, Mirzadeh S, Kennel SJ, Brechbiel MW. Improved in vivo stability of Actinium-225 macrocyclic complexes. J Med Chem. 1999;42:2988\u201392. https:\/\/doi.org\/10.1021\/jm990141f.","journal-title":"J Med Chem"},{"key":"5406_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.semnuclmed.2019.09.002","volume":"50","author":"JG Jurcic","year":"2020","unstructured":"Jurcic JG. Targeted alpha-particle therapy for hematologic malignancies. Semin Nucl Med. 2020;50:152\u201361. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.09.002.","journal-title":"Semin Nucl Med"},{"key":"5406_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.semnuclmed.2020.02.004","volume":"50","author":"C Kratochwil","year":"2020","unstructured":"Kratochwil C, Haberkorn U, Giesel FL. 225Ac-PSMA-617 for therapy of prostate cancer. Semin Nucl Med. 2020;50:133\u201340. https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.02.004.","journal-title":"Semin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05406-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05406-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05406-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T01:08:15Z","timestamp":1638493695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05406-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,12]]},"references-count":33,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5406"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05406-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,12]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies were performed per Institutional Animal Care and Use Committee protocol (IACUC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}